Zobrazeno 1 - 10
of 442
pro vyhledávání: ''
Autor:
Philippe Armand, Robert J. Soiffer, Joseph H. Antin, Areej El-Jawahri, Yi Bin Chen, Brett Glotzbecker, Vincent T. Ho, Corey Cutler, Sarah Nikiforow, Zachariah DeFilipp, Natasha Kekre, Rizwan Romee, Haesook T. Kim, Mahasweta Gooptu, Julia Hofer, John Koreth, Edwin P. Alyea, Prashant Nageshwar
Publikováno v:
Bone Marrow Transplantation. 56:1006-1012
The α4s7 integrin is upregulated on naive and memory T cell subsets in patients who subsequently develop gastrointestinal (GI) acute GVHD. Natalizumab (Tysabri®, Biogen Inc.) acts against the α4 subunit that mediates homing of lymphocytes to the G
Autor:
Patrizia Chiusolo, Sabrina Giammarco, Carmen Di Grazia, Maria Teresa Van Lint, Federica Sorà, Andrea Bacigalupo, Emanuele Angelucci, Anna Maria Raiola, Alida Dominietto, Luca Laurenti, Francesca Gualandi
Publikováno v:
Bone Marrow Transplantation. 54:708-712
This is an update on acute and chronic graft-versus-host disease (GvHD) in 425 patients with hematologic malignancies, undergoing an unmanipulated haploidentical (HAPLO) graft from related donors, with a modified post-transplant cyclophosphamide (PT-
Autor:
Stefania Bramanti, Didier Blaise, Faezeh Legrand, Valerio Maisano, Reda Bouabdallah, Luca Castagna, Pierre-Jean Weiller, Raynier Devillier, Djamel Mokart, Samia Harbi, Angela Granata, Jacopo Mariotti, Catherine Faucher, Chiara De Philippis, Barbara Sarina, Christian Chabannon, Norbert Vey, Sabine Furst, Boris Calmels, Claude Lemarie
Publikováno v:
Bone Marrow Transplantation. 54:1730-1737
While bone marrow (BM) grafts were initially used for T-replete HLA-haploidentical related donors transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy), the use of peripheral blood stem cell (PBSC) remains debated. We thus co
Autor:
Shigeo Fuji, Kazuyoshi Ishii, Kaname Miyashita, Atae Utsunomiya, Takahiro Fukuda, Makoto Yoshimitsu, Tetsuya Eto, Hiroshi Fujiwara, Hirokazu Okumura, Hiroyasu Ogawa, Junji Tanaka, Yoshifusa Takatsuka, Yoshiko Atsuta, Kenji Ishitsuka, Akira Yokota, Akihito Yonezawa, Koji Kato, Junichi Tsukada, Akinori Nishikawa
Publikováno v:
Bone Marrow Transplantation. 54:1266-1274
Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia-lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for gra
Autor:
Huixia Liu, Haitao Bai, Jun J. Yang, Shan Shao, Yu Cai, Su Li, Xianmin Song, Chun Wang, Liping Wan, Jieling Jiang, Jun Zhu
Publikováno v:
Bone Marrow Transplantation
Nowadays, the most wildly used regimens for graft-versus-host disease (GvHD) prophylaxis in haplo-hematopoietic stem cell transplantation (Haplo-HSCT) are based on in vivo T-cell depletion (TCD) with anti-thymocyte globulin (ATG) or posttransplant cy
Autor:
Rima M. Saliba, Amin M. Alousi, Uday R. Popat, Muzaffar H. Qazilbash, Simrit Parmar, Stefan O. Ciurea, Chitra Hosing, Gabriela Rondon, Mithun Vinod Shah, Partow Kebriaei, Betul Oran, Ioana Rus, Richard E. Champlin, Issa F. Khouri, Doris Soebbing, Julianne Chen
Publikováno v:
Bone Marrow Transplant
Allogeneic SCT for older patients remains challenging at least in part due to graft-versus-host disease (GVHD) and higher treatment-related mortality (TRM). We conducted a prospective pilot study primarily for older patients undergoing matched unrela
Autor:
Katie L. Kunze, Tania Jain, Daniel K. Partain, William J. Hogan, M'hamed Temkit, Veena Fauble, Lisa Z. Sproat, Vivek Roy, Jeanne Palmer, Mrinal S. Patnaik, Pierre Noel, James L. Slack, Jose F. Leis, Nandita Khera, Ruben A. Mesa
Publikováno v:
Bone Marrow Transplant
The aim of this study is to compare clinical outcomes of patients who underwent allogeneic stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) using either Busulfan Fludarabine (BuFlu), Fludarabine Bis-chloreth
Autor:
Sam Milliken, Ian Nivison-Smith, Sylvia Ai, Rodrigo Martino, Anthony J. Dodds, David D.F. Ma, Irene García-Cadenas, John Moore, Keith Fay, Chun Kei Kris Ma, Maria Laura Fox, Jorge Sierra
Publikováno v:
Bone Marrow Transplantation. 53:1478-1482
Publikováno v:
Bone Marrow Transplantation. 53:1124-1130
Pulmonary chronic graft-versus-host disease (p-CGVHD) following allogeneic HSCT is devastating with limited proven treatments. Although sporadically associated with pulmonary toxicity, the proteasome inhibitor bortezomib may be efficacious in p-CGVHD
Publikováno v:
Bone Marrow Transplantation. 53:900-904